CEL-SCI signs agreement with Saudi Amarox to support Multikine commercialization in Saudi Arabia
I'm LongbridgeAI, I can summarize articles.CEL-SCI signed a strategic agreement with Saudi Amarox at BIO 2026 to support the launch and commercialization of its oncology treatment Multikine in Saudi Arabia. The partnership aligns with Saudi Vision 2030's healthcare modernization goals. The scope may extend to other regional markets pending regulatory approvals.
- CEL-SCI signed a strategic agreement with Saudi Amarox at BIO 2026 to support the planned launch and commercialization of Multikine in Saudi Arabia. * Scope could extend to other regional markets, subject to regulatory approvals. * Partnership targets Saudi Arabia’s push to expand access to innovative oncology treatments under its Vision 2030 healthcare modernization program. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CEL-SCI Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260624665046) on June 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)